Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - bisacodyl 5mg - enteric coated tablet - 5 mg - active: bisacodyl 5mg excipient: carnauba wax hyprolose hypromellose methacrylic acid copolymer eudragit l 100 iron oxide yellow isopropyl alcohol lactose monohydrate magnesium stearate   methacrylic acid copolymer microcrystalline cellulose purified talc purified water   starch sucrose titanium dioxide triethyl citrate - short term relief of constipation

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - alanine 20.6 g;  ; arginine 13.95 g/l; aspartic acid 4.12 g/l;  ; glutamic acid 7.11 g/l; glycine 9.87 g/l;  ; histidine 8.49 g/l; isoleucine 7.11 g/l;  ; leucine 9.87 g/l;  ; lysine acetate 15.8 g/l equivalent to lysine 11.20 g/l; methionine 7.11 g/l;  ; phenylalanine 9.87 g/l;  ; proline 8.49 g/l; serine 5.62 g/l; threonine 7.11 g/l; tryptophan 2.37 g; tyrosine 0.37 g;  ; valine 9.11 g;  ; glucose monohydrate 302.5 g equivalent to glucose anhydrous 275 g;  ;  ; olive oil 140 g/l (refined, 80% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio); soya oil 35 g/l (refined, 20% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) - emulsion for infusion - active: alanine 20.6 g   arginine 13.95 g/l aspartic acid 4.12 g/l   glutamic acid 7.11 g/l glycine 9.87 g/l   histidine 8.49 g/l isoleucine 7.11 g/l   leucine 9.87 g/l   lysine acetate 15.8 g/l equivalent to lysine 11.20 g/l methionine 7.11 g/l   phenylalanine 9.87 g/l   proline 8.49 g/l serine 5.62 g/l threonine 7.11 g/l tryptophan 2.37 g tyrosine 0.37 g   valine 9.11 g   excipient: glacial acetic acid water for injection active: glucose monohydrate 302.5 g equivalent to glucose anhydrous 275 g     excipient: hydrochloric acid water for injection active: olive oil 140 g/l (refined, 80% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) soya oil 35 g/l (refined, 20% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) excipient: egg phosphatidyl esters glycerol sodium hydroxide sodium oleate water for injection - olimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient, or contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - alanine 20.6 g/l;  ; arginine 13.95 g/l; aspartic acid 4.12 g/l;  ; glutamic acid 7.11 g/l; glycine 9.87 g/l;  ; histidine 8.49 g/l; isoleucine 7.11 g/l;  ; leucine 9.87 g/l;  ; lysine acetate 15.8 g/l equivalent to lysine 11.20 g/l; magnesium chloride hexahydrate 1.52 g/l;  ; methionine 7.11 g/l;  ; phenylalanine 9.87 g/l;  ; potassium chloride 4.19 g/l;  ;  ; proline 8.49 g/l; serine 5.62 g/l; sodium acetate trihydrate 2.81 g/l;  ; sodium glycerophosphate 6.89 g/l; threonine 7.11 g/l; tryptophan 2.37 g/l; tyrosine 0.37 g/l;  ; valine 9.11 g/l;  ; calcium chloride dihydrate 1.94 g/l;  ; glucose monohydrate 302.5 g/l equivalent to glucose anhydrous 275.0 g/l;  ;  ; olive oil 140 g/l (refined, 80% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio); soya oil 35 g/l (refined, 20% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) - emulsion for infusion - active: alanine 20.6 g/l   arginine 13.95 g/l aspartic acid 4.12 g/l   glutamic acid 7.11 g/l glycine 9.87 g/l   histidine 8.49 g/l isoleucine 7.11 g/l   leucine 9.87 g/l   lysine acetate 15.8 g/l equivalent to lysine 11.20 g/l magnesium chloride hexahydrate 1.52 g/l   methionine 7.11 g/l   phenylalanine 9.87 g/l   potassium chloride 4.19 g/l     proline 8.49 g/l serine 5.62 g/l sodium acetate trihydrate 2.81 g/l   sodium glycerophosphate 6.89 g/l threonine 7.11 g/l tryptophan 2.37 g/l tyrosine 0.37 g/l   valine 9.11 g/l   excipient: glacial acetic acid water for injection active: calcium chloride dihydrate 1.94 g/l   glucose monohydrate 302.5 g/l equivalent to glucose anhydrous 275.0 g/l     excipient: hydrochloric acid water for injection active: olive oil 140 g/l (refined, 80% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) soya oil 35 g/l (refined, 20% for a total content of 175g/l to reach linoleic acid and alpha-linoleic acid ratio) excipient: egg phosphatidyl esters glycerol sodium hydroxide sodium oleate water for injection - olimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient, or contraindicated.

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

smith & nephew pty ltd - 33705 - prosthesis, internal, joint, wrist, total - total wrist implant system to provide balance and stability in the wrist joint for patients suffering pain and/or loss of function

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bisacodyl 5mg;   - enteric coated tablet - 5 mg - active: bisacodyl 5mg   excipient: acacia carnauba wax castor oil glycerol iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate   maize starch as 8.3mg dried starch and 1.5mg soluble starch methacrylic acid copolymer purified talc shellac sucrose titanium dioxide white beeswax

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bisacodyl 10mg;   - suppository - 10 mg - active: bisacodyl 10mg   excipient: hard fat

Australia - English - Department of Health (Therapeutic Goods Administration)

lmt surgical pty ltd - 35663 - total wrist carpus prosthesis - intended for the replacement of wrist joints disabled by pain, deformity and/or limited motion caused by: 1) non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis and avascular necrosis; 2) rheumatoid arthritis; 3) revision where other devices or treatments have failed; 4) scapholunate advanced collapse (slac) and other functional deformities; 5) trauma, including fractures of the carpal bones.

Australia - English - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 35670 - prosthesis, internal, joint, shoulder, total - total shoulder replacement prosthesis.